As per the data provided by the world ovarian cancer coalition atlas, in 2012 there were 239,000 cases, and 152,000 deaths worldwide from ovarian cancer, with some 600,000 women living within five years of a diagnosis. The American Cancer Society estimates for ovarian cancer in the United States for 2019 are that about 22,530 women will receive a new diagnosis of ovarian cancer and about 13,980 women will die from ovarian cancer.It is estimated that by 2035, incidence will increase to 371,000 a year (55%) and deaths will ...
Read More
As per the data provided by the world ovarian cancer coalition atlas, in 2012 there were 239,000 cases, and 152,000 deaths worldwide from ovarian cancer, with some 600,000 women living within five years of a diagnosis. The American Cancer Society estimates for ovarian cancer in the United States for 2019 are that about 22,530 women will receive a new diagnosis of ovarian cancer and about 13,980 women will die from ovarian cancer.It is estimated that by 2035, incidence will increase to 371,000 a year (55%) and deaths will increase by 67% to 254,000. Much progress has been made in diagnosis, surgery, chemotherapy molecules and protocols and surveillance guidelines; but it remains a reality that majority of advanced ovarian cancer patients treated with a curative intent will ultimately recur and succumb. Thus is warranted the exploration of treatments options and novel therapeutic strategies to address recurrent ovarian cancer patients. Today, more than ever, new therapies are coming to the fore and the armamentarium is richer than ever against ovarian cancer.
Read Less
